Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals

A minireview of recent literature

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The broad spectrum anti-neoplastic drug oxaliplatin is a third-generation platinum compound that inhibits DNA synthesis, mainly by causing intrastrandal cross-links in DNA. The drug is particularly useful alone and in combination with flurouracil and leucovorin in colorectal cancer, but it is also used for other cancers such as those of the ovary, lung, breast and liver, as well as non-Hodgkin's lymphoma. The drug is known to cause neurological, gastrointestinal and haematological toxicities. Neurotoxicity occurs in most of the treated patients and is considered to be a serious limitation for the use of the drug. The mechanism of the neurotoxicity is not known with certainty but may involve prolongation of sodium channels opening. Strategies to ameliorate oxaliplatin neurotoxicity include the use of several 'neuroprotective' drugs. This MiniReview attempts to list and comment on the action and use of some of these agents, which include carbamazepine, gabapentin, calcium and magnesium salts, reduced glutathione, N-acetylcysteine and a few others. None of these drugs have been proven to be effective in large, controlled, clinical trials.

Original languageEnglish
Pages (from-to)272-279
Number of pages8
JournalBasic and Clinical Pharmacology and Toxicology
Volume106
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

oxaliplatin
Animals
Pharmaceutical Preparations
Platinum Compounds
Leucovorin
Sodium Channels
DNA
Carbamazepine
Controlled Clinical Trials
Acetylcysteine
Neuroprotective Agents
Liver
Non-Hodgkin's Lymphoma
Magnesium
Glutathione
Toxicity
Colorectal Neoplasms
Ovary
Breast
Salts

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

@article{96a270af20d94755bd56e54f8fd226eb,
title = "Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: A minireview of recent literature",
abstract = "The broad spectrum anti-neoplastic drug oxaliplatin is a third-generation platinum compound that inhibits DNA synthesis, mainly by causing intrastrandal cross-links in DNA. The drug is particularly useful alone and in combination with flurouracil and leucovorin in colorectal cancer, but it is also used for other cancers such as those of the ovary, lung, breast and liver, as well as non-Hodgkin's lymphoma. The drug is known to cause neurological, gastrointestinal and haematological toxicities. Neurotoxicity occurs in most of the treated patients and is considered to be a serious limitation for the use of the drug. The mechanism of the neurotoxicity is not known with certainty but may involve prolongation of sodium channels opening. Strategies to ameliorate oxaliplatin neurotoxicity include the use of several 'neuroprotective' drugs. This MiniReview attempts to list and comment on the action and use of some of these agents, which include carbamazepine, gabapentin, calcium and magnesium salts, reduced glutathione, N-acetylcysteine and a few others. None of these drugs have been proven to be effective in large, controlled, clinical trials.",
author = "Ali, {Badreldin H.}",
year = "2010",
month = "4",
doi = "10.1111/j.1742-7843.2009.00512.x",
language = "English",
volume = "106",
pages = "272--279",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals

T2 - A minireview of recent literature

AU - Ali, Badreldin H.

PY - 2010/4

Y1 - 2010/4

N2 - The broad spectrum anti-neoplastic drug oxaliplatin is a third-generation platinum compound that inhibits DNA synthesis, mainly by causing intrastrandal cross-links in DNA. The drug is particularly useful alone and in combination with flurouracil and leucovorin in colorectal cancer, but it is also used for other cancers such as those of the ovary, lung, breast and liver, as well as non-Hodgkin's lymphoma. The drug is known to cause neurological, gastrointestinal and haematological toxicities. Neurotoxicity occurs in most of the treated patients and is considered to be a serious limitation for the use of the drug. The mechanism of the neurotoxicity is not known with certainty but may involve prolongation of sodium channels opening. Strategies to ameliorate oxaliplatin neurotoxicity include the use of several 'neuroprotective' drugs. This MiniReview attempts to list and comment on the action and use of some of these agents, which include carbamazepine, gabapentin, calcium and magnesium salts, reduced glutathione, N-acetylcysteine and a few others. None of these drugs have been proven to be effective in large, controlled, clinical trials.

AB - The broad spectrum anti-neoplastic drug oxaliplatin is a third-generation platinum compound that inhibits DNA synthesis, mainly by causing intrastrandal cross-links in DNA. The drug is particularly useful alone and in combination with flurouracil and leucovorin in colorectal cancer, but it is also used for other cancers such as those of the ovary, lung, breast and liver, as well as non-Hodgkin's lymphoma. The drug is known to cause neurological, gastrointestinal and haematological toxicities. Neurotoxicity occurs in most of the treated patients and is considered to be a serious limitation for the use of the drug. The mechanism of the neurotoxicity is not known with certainty but may involve prolongation of sodium channels opening. Strategies to ameliorate oxaliplatin neurotoxicity include the use of several 'neuroprotective' drugs. This MiniReview attempts to list and comment on the action and use of some of these agents, which include carbamazepine, gabapentin, calcium and magnesium salts, reduced glutathione, N-acetylcysteine and a few others. None of these drugs have been proven to be effective in large, controlled, clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=77949456097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949456097&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2009.00512.x

DO - 10.1111/j.1742-7843.2009.00512.x

M3 - Article

VL - 106

SP - 272

EP - 279

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 4

ER -